Skip to content

Evaluating the Efficacy of I-fiber Pearl on Reducing Body Fat Accumulation in Obese Subjects

Evaluating the Efficacy of I-fiber Pearl on Reducing Body Fat Accumulation in Obese Subjects: a Randomized, Double-blind, and Placebo-controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06203834
Enrollment
50
Registered
2024-01-12
Start date
2023-11-01
Completion date
2024-09-30
Last updated
2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Brief summary

The aim of this study is to investigate the effects of I-Fiber Pearl on Body Weight and Body Fat in Obese Adults.

Detailed description

This randomized, double-blinded,placebo-controlled clinical trial will be conduct for 12 weeks with fifty adults. Subjects will be recruited and randomly assigned into two groups: (1) placebo, n = 25; (2) I-Fiber Pearl, n=25. During the 12 weeks intervention, the subjects should take 200g placebo or 200g I-Fiber Pearl a day . The two pearl are supplied in plastic packages, and both the products taste the same. Subjects also should complete the assessment of anthropometric measurement, intestinal questionnaire , food record, urine, feces and blood collection at week 0 and week 12.

Interventions

DIETARY_SUPPLEMENTI-Fiber Pearl

Eat 200g for once, and once a day.

DIETARY_SUPPLEMENTplacebo

Eat 200g for once, and once a day.

Sponsors

ITSWAY BIOTECH INC.
CollaboratorUNKNOWN
Chung Shan Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* female * aged 20-50 years old * body mass index is greater than or equal to 27 kg/m2 * waist greater than or equal to 80 cm

Exclusion criteria

* Subjects diagnosed with cancer and on curative care. * Subjects diagnosed with heart disease and on curative care. * Subjects who use other drugs whose pharmacological effects may affect the experiment or may aggravate the effects of the drug. * Subjects with systemic infection requiring antibiotics.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline body weight at week 12Week 0, Week 12Compared the difference of body weight between the week 12 and 0.
Change from baseline body fat at week 12Week 0, Week 12Compared the difference of body fat between the week 12 and 0.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026